Antineoplastic Agents, Alkylating
Showing 1 - 25 of 6,360
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in United States (CYNK-001)
Recruiting
- Leukemia
- +19 more
- CYNK-001
-
Denver, Colorado
- +9 more
Sep 9, 2022
Breast Cancer, Gynecologic Cancer, HNSCC Trial in Boston (STX-478, Fulvestrant)
Recruiting
- Breast Cancer
- +3 more
-
Boston, MassachusettsMassachusetts General Hospital
Mar 13, 2023
Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem
Active, not recruiting
- Hematologic Malignancies
- +7 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Feb 28, 2022
Acute Myeloid Leukemia, MDS Trial in China (Fludarabine, busulfan and melphalan, Fludarabine and Busulfan)
Active, not recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Fludarabine, busulfan and melphalan
- Fludarabine and Busulfan
-
Fuzhou, Fujian, China
- +8 more
Aug 14, 2023
Tumors, Carcinoma, Squamous, Antineoplastic Agents Trial (Nivolumab Injection [Opdivo])
Not yet recruiting
- Neoplasms
- +2 more
- Nivolumab Injection [Opdivo]
- (no location specified)
Jul 19, 2023
Neuroendocrine Tumors Trial in France (Oxaliplatin-based chemo, Alkylating-based chemo)
Active, not recruiting
- Neuroendocrine Tumors
- Oxaliplatin-based chemotherapy
- Alkylating-based chemotherapy
-
Amiens, France
- +18 more
Mar 15, 2022
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma Trial in
Recruiting
- Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
-
Columbus, Ohio
- +9 more
Aug 1, 2022
NSCLC, Antineoplastic Agents Trial in Edmonton (Experimental intervention)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Antineoplastic Agents
- Experimental intervention
-
Edmonton, Alberta, CanadaCross Cancer Institute
May 23, 2022
Reporting of Antibody-Drug Conjugate Associated Sepsis-related
Completed
- Sepsis (SMQ)
- +2 more
- Antibody-Drug Conjugate
- Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
-
Changsha, Hunan, ChinaCentral South University
Jun 19, 2022
Tumors, Kidney Tumors, Urologic Tumors Trial in Nanjing (Toripalimab, Axitinib, Lenvatinib)
Recruiting
- Neoplasms
- +12 more
- Toripalimab
- +3 more
-
Nanjing, Jiangsu, ChinaJinling Hospital, Affiliated Hospital of Medical School, Nanjing
Oct 28, 2023
Hormone Receptor Positive Breast Carcinoma, Breast Tumors, Tumors, Breast Trial in Italy (Liquid biopsy and CT scan)
Recruiting
- Hormone Receptor Positive Breast Carcinoma
- +6 more
- Liquid biopsy and CT scan
-
Bergame, Bergamo, Italy
- +6 more
Apr 13, 2023
Reporting of AdVerse Events Associated With AnTicAncerRapy
Recruiting
- Cancer
- Antineoplastic and Immunomodulating Agents
-
Caen, Basse Normandie, FranceAlexandre Joachim
Jan 4, 2021
Urinary Bladder Tumors, Urologic Tumors, Urogenital Tumors Trial in Shanghai (tislelizumab and BCG)
Recruiting
- Urinary Bladder Neoplasms
- +5 more
- tislelizumab and BCG
-
Shanghai, Shanghai, ChinaRen Ji Hospital, School of Medicine, Shanghai Jiao Tong Universi
Jun 10, 2021
Multiple Myeloma, Tumor, Plasma Cell, Tumors by Histologic Type Trial in United States (CYNK-001)
Active, not recruiting
- Multiple Myeloma
- +19 more
- CYNK-001
-
Denver, Colorado
- +8 more
May 24, 2022
Leukemia, Myeloid, Acute, MDS Trial in Worldwide (CC-95251, Azacitidine)
Recruiting
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
-
Marina Del Rey, California
- +35 more
Mar 11, 2022
Adult Diffuse Large Cell Lymphoma, Recurrent, Adult Refractory DLBCL Trial in Canada (DPX-Survivac, Pembrolizumab,
Active, not recruiting
- Adult Diffuse Large Cell Lymphoma
- +2 more
- DPX-Survivac
- +2 more
-
Calgary, Alberta, Canada
- +5 more
Nov 9, 2022
Urothelial Carcinoma, Anlotinib, Urogenital Tumors Trial in Tianjin (Anlotinib, Cisplatin, Carboplatin)
Not yet recruiting
- Urothelial Carcinoma
- +6 more
- Anlotinib
- +3 more
-
Tianjin, ChinaTianjin Medical Unversity Second Hospital
Aug 30, 2021
Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)
Recruiting
- Lung Neoplasm Malignant
- +18 more
-
Fairfax, VirginiaNew Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022
Carcinoma, Carcinoma, Hepatocellular, Liver Tumors Trial in Guangzhou (Hepatic arterial infusion chemo, Folfox Protocol,
Not yet recruiting
- Carcinoma
- +8 more
- Hepatic arterial infusion chemotherapy
- +2 more
-
Guangzhou, Guangdong, ChinaLei Zhang
Sep 22, 2021
Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute, Biphenotypic Acute Leukemia Trial in Saint Petersburg (Fludarabine,
Recruiting
- Leukemia, Acute Lymphoblastic
- +5 more
- Fludarabine
- +5 more
-
Saint Petersburg, Russian FederationRM Gorbacheva Research Institute
Jul 19, 2022
CIPN and it's Impact on Quality of Life in Patients Receiving
Not yet recruiting
- Chemotherapy-induced Peripheral Neuropathy
- (no location specified)
Apr 24, 2023